疑似脓毒症相关低血压的限制性液体复苏(REFRESH):一项先导随机对照试验
本研究为前瞻性、随机、开放标签先导临床试验,纳入急诊就诊、疑似脓毒症且收缩压低于100 mmHg、已接受至少1000 ml静脉液体后的患者99例(限制性液体组50例,常规治疗组49例),比较最初6小时内限制性液体复苏方案与常规治疗。主要终点为随机后6小时内总液体量:限制性液体组中位数2387 ml(Q1-Q3 1750-2750 ml;30 ml/kg,Q1-Q3 32-39 ml/kg),常规治疗组3000 ml(Q1-Q3 2250-3900 ml;43 ml/kg,Q1-Q3 35-50 ml/kg),p < 0.001。血管升压药支持中位时间限制性液体组21小时(Q1-Q3 9-42小时) vs 常规治疗组33小时(Q1-Q3 15-50小时),p = 0.13;90天死亡限制性液体组4/48(8%) vs 常规治疗组3/47(6%)。方案偏离限制性液体组6/50(12%) vs 常规治疗组11/49(22%),严重不良事件两组各4例(8%)。作者认为该方案在急诊疑似脓毒症低血压患者中似乎可行,疾病严重程度中等且死亡率低,未来需招募高危患者进一步试验以确定对临床结局的影响。
要点
- 纳入标准:急诊疑似脓毒症、收缩压低于100 mmHg、已接受至少1000 ml静脉液体。
- 限制性液体组6小时内总液体量中位数2387 ml(Q1-Q3 1750-2750 ml;30 ml/kg,Q1-Q3 32-39 ml/kg),常规治疗组3000 ml(Q1-Q3 2250-3900 ml;43 ml/kg,Q1-Q3 35-50 ml/kg),p < 0.001。
- 血管升压药支持中位时间限制性液体组21小时(Q1-Q3 9-42小时) vs 常规治疗组33小时(Q1-Q3 15-50小时),p = 0.13。
- 90天死亡限制性液体组4/48(8%) vs 常规治疗组3/47(6%)。
- 方案偏离限制性液体组6/50(12%) vs 常规治疗组11/49(22%);严重不良事件两组各4例(8%)。
适用人群与场景
- 急诊科就诊、疑似脓毒症且收缩压低于100 mmHg、已接受至少1000 ml静脉液体后的患者。
研究设计与关键结果
- 研究类型:前瞻性、随机、开放标签先导临床试验;样本量99例(限制性液体组50例,常规治疗组49例)。
- 主要终点:随机后6小时内总液体量,限制性液体组中位数2387 ml(Q1-Q3 1750-2750 ml;30 ml/kg,Q1-Q3 32-39 ml/kg) vs 常规治疗组3000 ml(Q1-Q3 2250-3900 ml;43 ml/kg,Q1-Q3 35-50 ml/kg),p < 0.001。
- 次要终点:血管升压药支持中位时间限制性液体组21小时(Q1-Q3 9-42小时) vs 常规治疗组33小时(Q1-Q3 15-50小时),p = 0.13。
- 90天死亡:限制性液体组4/48(8%) vs 常规治疗组3/47(6%)。
- 方案偏离:限制性液体组6/50(12%) vs 常规治疗组11/49(22%);严重不良事件两组各4例(8%)。
证据类型、等级与局限
- 证据类型:前瞻性、随机、开放标签先导临床试验。
- 局限:作者指出疾病严重程度中等且死亡率低,未来需招募高危患者进一步试验以确定对临床结局的影响。
对床旁实践的改变
- 作者认为,对急诊疑似脓毒症低血压患者,限制性液体加早期血管升压药方案似乎可行。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: To determine if a regimen of restricted fluids and early vasopressor compared to usual care is feasible for initial resuscitation of hypotension due to suspected sepsis.
METHODS: A prospective, randomised, open-label, clinical trial of a restricted fluid resuscitation regimen in the first 6 h among patients in the emergency department (ED) with suspected sepsis and a systolic blood pressure under 100 mmHg, after minimum 1000 ml of IV fluid. Primary outcome was total fluid administered within 6 h post randomisation.
RESULTS: There were 99 participants (50 restricted volume and 49 usual care) in the intention-to-treat analysis. Median volume from presentation to 6 h in the restricted volume group was 2387 ml [first to third quartile (Q1-Q3) 1750-2750 ml]; 30 ml/kg (Q1-Q3 32-39 ml/kg) vs. 3000 ml (Q1-Q3 2250-3900 ml); 43 ml/kg (Q1-Q3 35-50 ml/kg) in the usual care group (p < 0.001). Median duration of vasopressor support was 21 h (Q1-Q3 9-42 h) vs. 33 h (Q1-Q3 15-50 h), (p = 0.13) in the restricted volume and usual care groups, respectively. At 90-days, 4 of 48 (8%) in the restricted volume group and 3 of 47 (6%) in the usual care group had died. Protocol deviations occurred in 6/50 (12%) in restricted group and 11/49 (22%) in the usual care group, and serious adverse events in four cases (8%) in each group.
CONCLUSIONS: A regimen of restricted fluids and early vasopressor in ED patients with suspected sepsis and hypotension appears feasible. Illness severity was moderate and mortality rates low. A future trial is necessary with recruitment of high-risk patients to determine effects on clinical outcomes in this setting.
参考来源
- Macdonald SPJ, Keijzers G, Taylor DM, et al. Restricted fluid resuscitation in suspected sepsis associated hypotension (REFRESH): a pilot randomised controlled trial. Intensive Care Med. 2018. PMID: 30382308. doi:10.1007/s00134-018-5433-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。